Advertisement
Home Press Releases ACCP and ASCO Joint LC Screening

ACCP and ASCO Joint LC Screening

Clinical Practice Guideline, CT Screening, Lung Cancer, Smokers, Former Smokers

(NORTHBROOK, IL, MAY 21, 2012)—The American College of Chest Physicians (ACCP) and the American Society of Clinical Oncology (ASCO) have released a joint systematic review and clinical practice guideline on the role of CT screening for lung cancer. The guideline recommendations and systematic review are published online in The Journal of the American Medical Association.

The guideline recommendations are based on a systematic review of the evidence, informed by the full body of research on lung cancer screening. The review was a collaboration of ACCP, ASCO, the American Cancer Society, and the National Comprehensive Cancer Network, with input from the American Thoracic Society (ATS). The review forms the basis of clinical practice guidelines developed by the ACCP and ASCO and was endorsed by ATS.

The guideline recommendations address CT screening for lung cancer in high-risk individuals who are smokers or former smokers. Specifically, the guideline recommends the following (please consult the guideline for full remarks and explanation of recommendations):

  • For smokers and former smokers who are age 55 to 74 and who have smoked for 30 pack years or more and either continue to smoke or have quit within the past 15 years, we suggest that annual screening with low-dose CT should be offered over both annual screening with chest radiograph or no screening, but only in settings that can deliver the comprehensive care provided to National Lung Screening Trial participants. (Grade of evidence 2B, indicating a ‘weak recommendation based on moderate quality research data’)
  • For individuals who have accumulated fewer than 30 pack years of smoking or are either younger than age 55 or older than 74, or individuals who quit smoking more than 15 years ago, and for individuals with severe comorbidities that would preclude potentially curative treatment and/or limit life expectancy, we suggest that CT screening should not be performed. (Grade of evidence 2C, indicating a ‘weak recommendation based on low quality research data’)

To access the full systematic review, click on the link below:

Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review

Advertisement